

SHORT-TERM EFFECTIVENESS AND SAFETY OF MIRIKIZUMAB IN ULCERATIVE COLITIS: REAL-WORLD EVIDENCE FROM THE ENEIDA REGISTRY OF GETECCU

María Dolores Martín-Arranz

UEG Week Berlin 2025

Poster

IBD

October 7, 2025

Real-world study of 171 ulcerative colitis patients from 43 Spanish hospitals shows mirikizumab achieved 30% clinical remission at week 12 in a highly treatment-refractory population.

KEY POINTS

- Clinical remission rates were 26% at week 8 and 30% at week 12, with clinical response rates of 44% and 45% respectively, in patients with median partial Mayo score 5 at baseline.
- The cohort was highly refractory with 89% prior anti-TNF exposure, 69% vedolizumab, 54% ustekinumab, 40% JAK inhibitors, and 54% exposed to more than 2 mechanisms of action.
- Prior exposure to only 1 mechanism of action was associated with significantly higher week-12 remission rates compared to 2 or more mechanisms (65% vs 25% and 27%, $p=0.04$ and $p=0.02$).
- Faecal calprotectin decreased significantly from 557 ug/g at baseline to 160 ug/g at week 12 ($p=0.001$), with hospitalization rate 5.8% and colectomy rate 1.7%.
- Safety profile was favorable with 10% reporting adverse events and only one severe event; this real-world data is most relevant for clinicians managing highly treatment-experienced ulcerative colitis patients.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/78959996-a813-11f0-850f-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.